ClinicalTrials.gov
ClinicalTrials.gov Menu

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02962388
Recruitment Status : Active, not recruiting
First Posted : November 11, 2016
Last Update Posted : July 18, 2018
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
French Innovative Leukemia Organisation

October 5, 2016
November 11, 2016
July 18, 2018
January 2017
November 2018   (Final data collection date for primary outcome measure)
Failure-free patients [ Time Frame: month 12 ]
Failure is defined by the occurrence of either intolerance and/or resistance to the second line therapy according to the protocol criteria
Same as current
Complete list of historical versions of study NCT02962388 on ClinicalTrials.gov Archive Site
  • Complete hematologic response [ Time Frame: 48 months ]
    Number of Participants With normal Laboratory Values
  • AE/SAE [ Time Frame: 48 months ]
    Rates, types and grades of AE/SAE related to the therapy, according to the NCI-CTCAE v4.0 classification
  • Median dose [ Time Frame: 48 months ]
    Median dose of the treatment received
  • Thrombotic and hemorrhagic events [ Time Frame: 48 months ]
    Cumulative incidence of thrombotic and hemorrhagic events incidence of progression into PV, secondary MF and MDS/acute leukemia
  • Quality of life questionnaire [ Time Frame: 48 months ]
    Quality of life
Same as current
Not Provided
Not Provided
 
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study
Prospective national multicenter randomized open label phase IIb RUXBETA trial.
A randomized, open label, multicenter phase IIb study to evaluate the efficacy and safety of Ruxolitinib versus best available therapy in patients with high risk essential thrombocythemia, who are resistant or intolerant to hydroxyurea.
Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Essential Thrombocythemia
  • Drug: Anagrelide
    Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
    Other Name: ARM A
  • Drug: Ruxolitinib (JAKAVI®)
    Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
    Other Name: ARM B
  • Drug: IFNα/ PegIFNα
    IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
    Other Name: ARM A
  • Active Comparator: Reference therapy arm
    Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
    Interventions:
    • Drug: Anagrelide
    • Drug: IFNα/ PegIFNα
  • Experimental: Investigational therapy arm

    Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.

    Maximum dose 25 mg BID.

    Intervention: Drug: Ruxolitinib (JAKAVI®)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
13
280
November 2022
November 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Target Population

  • Men and women, age more than or equal18 years and less than 75 years.
  • Confirmed diagnosis of Essential Thrombocythemia for at least 6 months, according to the 2008 WHO criteria, with a high-risk status.
  • Patients must have a treatment history for ET that meet the definition of resistance or intolerance to hydroxyurea therapy according to the ELN criteria as follow:

    • Platelets more than 600.0109/L after 3 months (12 weeks) of treatment at a dose over 2g/day.
    • Platelets more than 400.0 109/L and WBC less than 2.5109/L, whatever the dose of HU.
    • Platelets more than 400.0 109/L and Hb less than 10g/dl whatever the dose of HU.
    • Leg ulcers or other unacceptable muco-cutaneous toxicity.
    • HU-related fever.
  • ECOG Performance Status (ECOG PS) less than or equal 2 at screening and at baseline.

Adequate Organ Function:

  • Direct bilirubin less than 2.0 times the institutional Upper Limit of Normal (ULN).
  • Hepatic enzymes (AST, ALT) less than or equal 2.5 times the institutional ULN.
  • Adequate renal function at screening as demonstrated by MDRD-eGFR more than 30 mL/min/1.73m2.
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy during and after the study.

    • A male subject of fathering potential must use an adequate method of contraception to avoid conception during and after the study to minimize the risk of pregnancy.
    • For females and males, these restrictions apply for 24 hours after the last dose of study drug.
  • Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin hCG pregnancy test at Screening.
  • Signed Written Informed Consent.
  • Health insurance coverage.

Exclusion Criteria:

  • Patients with thrombocytosis related to another MPN than ET
  • Patients previously treated with a JAK2 inhibitor, Anagrelide or Interferon-alpha and prior history of therapy other than Hydroxyurea
  • Contraindication to Ruxolitinib, Anagrelide or Interferon-alpha (if no eligible for anagrelide), hypersensitivity to an excipient

Medical history and concurrent diseases:

  • Clinically significant cardiac disease (NYHA Class III or IV).
  • Chronic hepatocellular disease.
  • Subjects with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Ruxolitinib
  • Subjects with clinically significant bacterial, fungal, parasitic or viral infection which requires therapy:

    • Subjects with acute bacterial infections requiring antibiotic use should delay screening/enrolment until the course of antibiotic therapy has been completed.
    • Subjects with active hepatitis A, B or C or with HIV positivity at screening.
    • Subjects with diagnosed primary immunodeficiency syndromes such as X-Linked a gammaglobulinemia and common variable immune deficiency.
    • Subject with medical history of tuberculosis
  • History of progressive multifocal leucoencephalopathy (PML).
  • Other malignant disease during the last 5 years prior to the inclusion except treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, with no evidence for recurrence in the past 3 years.
  • History of significant bleeding disorder not related to the ET.

    • Diagnosed congenital bleeding disorders,
    • Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VIII antibodies),
    • Ongoing or recent (3 months) significant gastrointestinal bleeding.
  • Subjects with an uncontrolled undercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol.
  • Subjects being treated concurrently with a potent systemic inhibitor of CYP3A4 at the time of screening.
  • Subjects being treated concurrently with any prohibited medications.
  • Women who are pregnant or breastfeeding are not eligible for this study.
  • Inability to freely provide consent through judiciary or administrative condition.
  • Ongoing participation to another clinical investigational study.
Sexes Eligible for Study: All
18 Years to 74 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT02962388
RUXBETA trial
Yes
Not Provided
Plan to Share IPD: Yes
Plan Description: e crf
French Innovative Leukemia Organisation
French Innovative Leukemia Organisation
Novartis Pharmaceuticals
Principal Investigator: Stéphane GIRAUDIER, MD PD France Intergroupe Syndromes Myéloprolifératifs
Principal Investigator: LYDIA ROY, MD France Intergroupe Syndromes Myéloprolifératifs
French Innovative Leukemia Organisation
July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP